Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19

被引：0

作者：

Mohsenian Naghani, Shaghayegh ^{[1
]}

Jansen, Mark M. P. M. ^{[1
]}

Jaspers, Tessa ^{[1
]}

Bastiaans, Diane ^{[2
]}

Burger, David ^{[3
]}

机构：

[1] Elisabeth TweeSteden Ziekenhuis, Pharm, Tilburg, Netherlands

[2] Catharina Hosp, Clin Pharm, Eindhoven, Netherlands

[3] Radboudumc, Pharm, Nijmegen, Netherlands

来源：

EUROPEAN JOURNAL OF HOSPITAL PHARMACY | 2023年 / 30卷 / E1期

关键词：

COVID-19; drug administration routes; virology; HIV; critical care; HUMAN HEPATOCYTES; EXPRESSION; PHARMACOKINETICS; FORMULATION; CYTOKINES; MODEL; SARS;

D O I：

10.1136/ejhpharm-2020-002596

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Objective Lopinavir/ritonavir (LPV/RTV) exposure is decreased in children after crushing the tablets. Whether exposure is also decreased in adult patients is not known. This study evaluated the exposure of LPV/RTV in adult patients after administration of crushed LPV/RTV tablets. Methods Blood samples were drawn from patients with COVID-19 who were receiving crushed LPV/RTV 400/100 mg tablets twice daily. Results Plasma concentrations for 11 patients with COVID-19 (eight men, mean age 62.6 years) were included. The measured plasma concentrations of LPV were substantially higher than reported for patients with HIV. Conclusions There is adequate exposure from crushed LPV/RTV tablets, but because of limited experience, therapeutic drug monitoring is still advised.

引用

页码：E106 / E108

页数：3

共 21 条

[1] ABDELRAZZAK Z, 1993, MOL PHARMACOL, V44, P707
[2] The role of formulation on the pharmacokinetics of antiretroviral drugs
Bastiaans, Diane E. T.
Cressey, Tim R.
Vromans, Herman
Burger, David M.
[J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2014, 10 (07) : 1019 - 1037
[3] Application of in vitro biopharmaceutical methods in development of immediate release oral dosage forms intended for paediatric patients
Batchelor, Hannah K.
Kendall, Richard
Desset-Brethes, Sabine
Alex, Rainer
Ernest, Terry B.
[J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2013, 85 (03) : 833 - 842
[4] Pharmacokinetics of Lopinavir/Ritonavir Crushed Versus Whole Tablets in Children
Best, Brookie M.
Capparelli, Edmund V.
Diep, Huy
Rossi, Steven S.
Farrell, Michael J.
Williams, Elaine
Lee, Grace
van den Anker, John N.
Rakhmanina, Natella
[J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2011, 58 (04) : 385 - 391
[5] Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset
Chan, Jasper Fuk-Woo
Yao, Yanfeng
Yeung, Man-Lung
Deng, Wei
Bao, Linlin
Jia, Lilong
Li, Fengdi
Xiao, Chong
Gao, Hong
Yu, Pin
Cai, Jian-Piao
Chu, Hin
Zhou, Jie
Chen, Honglin
Qin, Chuan
Yuen, Kwok-Yung
[J]. JOURNAL OF INFECTIOUS DISEASES, 2015, 212 (12) : 1904 - 1913
[6] Chan K. S., 2003, Hong Kong Medical Journal, V9, P399
[7] In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds
Chen, F
Chan, KH
Jiang, Y
Kao, RYT
Lu, HT
Fan, KW
Cheng, VCC
Tsui, WHW
Hung, IFN
Lee, TSW
Guan, Y
Peiris, JSM
Yuen, KY
[J]. JOURNAL OF CLINICAL VIROLOGY, 2004, 31 (01) : 69 - 75
[8] Repression of PXR-mediated induction of hepatic CYP3A gene expression by protein kinase C
Ding, XS
Staudinger, JL
[J]. BIOCHEMICAL PHARMACOLOGY, 2005, 69 (05) : 867 - 873
[9] European Medicines Agency (EMA), 2020, EUR PUBL ASS REP EPA
[10] Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing
Kacevska, Marina
Robertson, Graham R.
Clarke, Stephen J.
Liddle, Christopher
[J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2008, 4 (02) : 137 - 149

← 1 2 3 →